No connection

Search Results

IPHA vs OWLT

IPHA
Innate Pharma S.A.
BEARISH
Price
$1.41
Market Cap
$132.2M
Sector
Healthcare
AI Confidence
90%
OWLT
Owlet, Inc.
BEARISH
Price
$4.94
Market Cap
$139.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
IPHA
--
OWLT
--
Forward P/E
IPHA
-2.25
OWLT
92.63
P/B Ratio
IPHA
-5.18
OWLT
6.99
P/S Ratio
IPHA
14.69
OWLT
1.32
EV/EBITDA
IPHA
-2.29
OWLT
-15.98

Profitability

Gross Margin
IPHA
0.0%
OWLT
50.64%
Operating Margin
IPHA
-689.55%
OWLT
-18.4%
Profit Margin
IPHA
0.0%
OWLT
-37.54%
ROE
IPHA
--
OWLT
-802.47%
ROA
IPHA
-38.85%
OWLT
-7.64%

Growth

Revenue Growth
IPHA
-46.7%
OWLT
29.6%
Earnings Growth
IPHA
--
OWLT
--

Financial Health

Debt/Equity
IPHA
--
OWLT
0.42
Current Ratio
IPHA
1.27
OWLT
1.85
Quick Ratio
IPHA
1.14
OWLT
1.32

Dividends

Dividend Yield
IPHA
--
OWLT
--
Payout Ratio
IPHA
0.0%
OWLT
0.0%

AI Verdict

IPHA BEARISH

IPHA exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a negative Price-to-Book ratio of -5.18, indicating negative shareholder equity. The company is experiencing a collapse in top-line growth with revenue declining 46.7% YoY, coupled with an unsustainable operating margin of -689.55%. While analysts maintain a 'strong_buy' rating with a $6.00 target, this is fundamentally disconnected from the current data-driven trajectory of value destruction and operational losses.

Strengths
Strong analyst consensus (Strong Buy) suggesting potential pipeline value not captured in financials
Current ratio of 1.27 provides a minimal short-term liquidity cushion
Recent slight 1-week price recovery (+2.9%)
Risks
Negative Book Value (P/B -5.18) indicating insolvency or severe capital erosion
Catastrophic operating margins (-689.55%)
Significant revenue contraction (-46.7% YoY)
OWLT BEARISH

OWLT exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of financial health metrics. While the company maintains strong revenue growth (29.6% YoY) and a healthy gross margin (50.64%), these are completely offset by catastrophic profitability, evidenced by an ROE of -802.47% and a massive collapse in EPS. The stock is in a clear technical downtrend, losing nearly 48% of its value in the last six months, and is further pressured by bearish insider activity from the CEO and CFO. Despite a high analyst target price of $14.25, the deterministic data suggests a high-risk profile with no clear path to near-term profitability.

Strengths
Strong YoY revenue growth of 29.60%
Healthy gross margin of 50.64%
Reasonable current ratio (1.85) indicating short-term liquidity
Risks
Critical financial health (Piotroski F-Score 1/9)
Extreme negative ROE (-802.47%) indicating massive capital erosion
Severe earnings collapse with Q/Q EPS growth of -1400%

Compare Another Pair

IPHA vs OWLT: Head-to-Head Comparison

This page compares Innate Pharma S.A. (IPHA) and Owlet, Inc. (OWLT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile